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A B S T R A C T
The aim of this study was to determine the efficacy and safety of montelukast added to previous medication in the
treatment of a mild and moderate asthma. Data were obtained via questionnaires given to the physicians and given
further to their patients. Patients were divided in two groups, first followed 4 weeks (612 patients) and second followed
8 weeks (91 patients). We found out that there was a significant improvement in FEV1 (forced expiratory volume in first
second) and general condition of patients and decreased number of salbutamol inhalations after using montelukast. In
the second group of patients we find out the same significant improvement in FEV1, general condition and decrease in
salbutamol inhalations after 4 weeks of using montelukast and further improvement after the next month of therapy.
We conclude that montelukast is an efficient drug with little side effects and with a good compliance. Montelukast
managed to achieve a good asthma control; therefore it has a significant place in asthma therapy.
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Introduction
Asthma is one of the most common chronic diseases
in the world with prevalence of 10–15% in children and
5–10% in adults in the western world1. In Croatia, 3–4
% of patients suffer from asthma2. Despite development
in understanding mechanisms of the disease and avail-
ability of inhalation therapy asthma frequency is in-
creasing both in children and adults. Therefore, during
90’s GINA (Global Initiative for Asthma)3 was created to
help health care professionals and public health officials
to reduce asthma prevalence, morbidity and mortality.
Asthma is today defined as a chronic inflammatory dis-
ease of the airways. Chronically inflamed airways are
hyper-responsive, they become obstructed and airflow is
limited (by bronchoconstriction, mucus plugs, edema
and increased inflammation) when airways are exposed
to various stimuli or triggers. Common asthma triggers
include viral infections, allergens such as domestic dust
mites, animals with fur, cockroaches, pollens, tobacco
smoke, air pollution, exercise, strong emotional expres-
sions and chemical irritants. Asthma attacks are epi-
sodic but airway inflammation is chronically present.
Therefore, asthma requires a long-term management
and cannot be cured but should be well controlled. It can
be treated and controlled so that patients can prevent
day and night symptoms, prevent serious attacks, need
little or no quick-relief medications, have productive,
physically active lives and have (near) normal lung
function. According to GINA asthma is classified in two
major groups: intermittent and persistent asthma. Per-
sistent is further divided into mild, moderate and se-
vere3. This classification is done according to the pres-
ence of day and night symptoms and lung function (PEF,
FEV1).
Regarding the GINA guidelines, asthma therapy is
applied. Today, there are many drugs used for asthma
treatment. All medications are divided in two groups:
quick-relief medications (or relievers) that work fast to
stop attacks or relieve symptoms, and long-term preven-
tive medications with anti-inflammatory effects (or con-
trollers). In both groups inhaled medications are pre-
ferred because of their high therapeutic ratio: high
concentrations of drug are delivered directly to the air-
ways with potent therapeutic effects and with few sys-
temic side effects. Corticosteroids, sodium chromoglycate,
nedocromil, long-acting 2 agonists, sustained release
theophylline and ketotifen are long-term preventive me-
dications. Inhaled steroids are the most effective anti-
-inflammatory therapy4. And drugs like short-acting 2
agonists, anticholinergics and short-acting theophylline
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are quick-relief medications. All mentioned drugs have
been used for asthma treatment for many years.
Therefore, many inflammatory molecules take part
in pathophysiology of asthma: IL-4, IL-5, IL-13, hista-
mine, leukotrienes, chemochines, etc.5 In the last twen-
ty years, only one new group of drugs has been discov-
ered and implemented in everyday practice for asthma
management – leukotriene antagonists6. History of leu-
kotrienes can be tracked back to classical pharmacology
studies in late 1930s. Leukotrienes were then named
slow released substance (SRS)7. Decades later, Brock-
lerhurst (1960)8 renamed it in SRS – A (Slow-reacting
substance of anaphylaxis). Two pivotal discoveries were
required before the importance of SRS – A in allergic re-
sponses were proven. The first was the discovery in
1973 by Augstein et al.9, when SRS – A antagonist
called FPL 55712 was discovered, and the second was
elucidation of the structure of SRS – A as a 5-lipooxy-
genase product of arachidonic acid, which was termed
cysteinyl leukotriene10. Since then, great efforts were
done to try to inhibit leukotriene synthesis by inhibiting
5-lipooxygenase or to block leukotriene receptors. There-
fore, first was discovered leukotriene receptor antagonist
zafirlukast (l990)11, then leukotriene-synthesis inhibitor
zileuton (1991)12 and finally in 1995 another leukotriene
receptor antagonist montelukast13. The first leukotriene
antagonist registrated in Croatia was montelukast.
The aim of this study was to determine the efficacy




The study was done between October 2000 and
March 2001 all over Croatia. Data were obtained by
questionnaires given to pulmonologists all over Croatia.
Each pulmonologist was given ten questionnaires to
give it further to their patients. Study population con-
sisted of 703 patients from 83 pulmonologists. Study
population was further divided in two groups. One
group of patients consisted of 612 patients from 73
pulmonologists and was followed in two time points (be-
fore and 4 weeks after using montelukast). The second
group consisted of 91 patients from 10 pulmonologists
and was followed at three time points (before using
montelukast, then 4 and 8 weeks after using monte-
lukast). Severity of asthma was classified according to
GINA criteria (intermittent and mild, moderate and se-
vere persistent asthma). In all patients montelukast
was prescribed as add on therapy to previous asthma
medication that they have taken during the last three
months. The montelukast (10 mg) was taken at 9 p.m.
and FEV1 was measured at 9 a.m..
Questionnaire
The questionnaire contained questions about asthma
therapy (prescribed drugs and their combinations, taken
drugs and their combinations) and presence of asthma
symptoms before and after use of montelukast. The set
of questions in group of patients followed in two time
points were as follows: What drugs do you prescribe?
What drugs do you take? Perception of well being before
and after using montelukast (scale from –3.0 to +3.0,
where –3.0 is the worst and +3.0 is the best)? Number of
inhalations of salbutamol per day before and after use of
montelukast? FEV1 before and after use of montelu-
kast? Physicians' evaluation of benefit of montelukast
usage? Benefit of montelukast on frequency of night
symptoms of asthma? Benefits and side effects of mon-
telukast according to physicians and patients?
The set of questions in the group of patients followed
in three time points (patients were followed before and 4
and 8 weeks after use of montelukast) was as follows:
General condition of patients before and after use of
montelukast? FEV1 before and after using montelukast?
Number of salbutamol inhalations before and after us-
ing montelukast?
Statistical analysis
The data are presented in absolute and relative fre-
quencies of various answers. The statistical significance
was assessed by the test of the significance of the differ-
ences of proportions and the Kruskal-Wallis ANOVA
test. Statistical analyses were performed using the
SPSS software for Windows (SPSS Inc., Chicago, Illi-
nois, USA). The results were considered statistically
significant for p values less than 0.05.
Results
We analyzed 612 questionnaires completed by 612
patients from 73 pulmonologist followed in two time
points and 91 questionnaires completed by 91 patients
and 10 pulmonologists followed in three time points.
The most often prescribed drugs for therapy of asthma
are as follows: inhaled corticosteroids which were pre-
scribed in 483 patients (79%), then long-lasting 2-ago-
nists (437 patients, 71%), long-lasting theophyllines
(203 patients, 33%), oral corticosteroids (86 patients,
14%), antihistamines (60 patients, 10%), intravenous
aminophylline (10 patients, 2%) and chromones (6 pa-
tients, 1 %).
The patients in the first group were followed in two
time points, before and after use of montelukast. In the
first group there were 73 pulmonologists with ten ques-
tionnaires each, and the questionnaires were at the end
given to 612 patients.
We compared FEV1 before and after using monte-
lukast for four weeks in 462 patients regarding level of
asthma according to GINA classification. In the group of
patients with intermittent asthma (27 patients) there
was improvement in FEV1 from 89% to 94%. In patients
with a mild persistent asthma (185 patients) we noticed
improvement from 79% to 85% in FEV1, and in the pa-
tients with a moderate persistent asthma (250 patients)
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FEV1 was improved from 64% to 73%. Differences in all
groups were statistically significant, p<0.05, (Figure 1).
Further, we compared number of salbutamol inhala-
tions per day in 381 patients before and after use of
montelukast regarding level of asthma according to the
GINA guidelines. In the group of patients with intermit-
tent asthma (19 patients) a number of salbutamol inha-
lations remained the same before and after use of mon-
telukast, 0.7 per day. In the group of patients with a
mild persistent asthma (157 patients) we noticed de-
crease in salbutamol inhalations per day from 1.4 to 1.0
after use of montelukast which was statistically signifi-
cant, p<0.05. And in the group of patients with a moder-
ate persistent asthma (205 patients) we also noticed sta-
tistically significant (p<0.05) decrease in salbutamol
inhalations per day from 2.7 to 1.9, (Figure 2).
Next we compared a general condition (scale –3.0 to
3.0) of 474 patients before and after use of montelukast
regarding level of asthma according to GINA. In the pa-
tients with intermittent asthma (29 patients) there was
improvement from score 1.3 to 2.2. In the patients with
a mild persistent asthma (190 patients) we noticed im-
provement from 0.9 to 2.0. In the patients with a moder-
ate persistent asthma (255 patients) there was increase
from score –0.2 to 1.5. Changes in general condition in
all groups were statistically significant, p<0.05, (Figure 3).
Further, we tried to estimate the benefit of montelu-
kast on a general condition of patients from pulmo-
nologists’ point of view using the same questionnaires.
Benefit of montelukast estimated by pulmonologists
was as follows: 110 patients were estimated as 3,0
(21%), 165 patients 2,0 (33%), 109 patients 1,0 (21%), 46
patients had 0 (9%), 27 patients had – 1,0 (5%), then 15
patients – 2,0 (3%) and 41 patients had – 3,0 (8%). In to-
tal, 46 patients (9%) have no changes in their condition
after use of montelukast, 384 patients (75%) have im-
provement in their condition after use of montelukast,
and only 83 patients (16%) have worsening in their con-
dition although they have used montelukast.
The benefits of montelukast estimated by pulmo-
nologists were as follows: decreased use of standard ther-
apy (inhaled corticosteroids, 2-agonists) in 135 patients
(22%), improvement in FEV1 in 85 patients (14%), disap-
pearance of night symptoms and cough in 72 patients
(12%), quick acting in 49 patients (8%), no need for sal-
butamol in 48 patients (8%), dealing better with physical
activity in 34 patients (6%), possibility of reducing dosage
of inhaled corticosteroids in 28 patients (5%), normal
physical findings over lung in 27 patients (4%), reduced
number of worsening of asthma, shorter and less intense
asthma attacks in 21 patients (3%) and reduced number
of exacerbations in 10 patients (2%), (Table 1).
The benefits of montelukast observed by patients
were as follows: I feel good, stoppage of cough in 130 pa-
tients (21%), stoppage of night symptoms in 80 patients
(13%), decreased number and less intense and shorter
attacks of dyspnea in 71 patients (12%), less using sal-
butamol in 65 patients (11%), no dyspnea in physical ac-
tivity in 59 patients (10%), I feel healthy, have better
quality of life, satisfied in 51 patients (8%), I feel no
problems with my nose nor breathing in 50 patients
(8%), I breath easily, feeling of heaviness in lungs have
decreased in 24 patients (4%), decreased need for corti-
costeroid and antihistamines in 4 patients (1%), (Table 2).
























Fig 1. FEV1 (forced expiratory volume in first second) before
and 4 weeks after use of montelukast (differences in all groups





















Fig. 2. Number of salbutamol inhalations before and 4 weeks
after using montelukast (differences in all groups are statisti-


























Fig. 3. Patients general condition before and 4 weeks after use of
montelukast (scale from –3.0 to 3.0).
The second group of patients (91 patients from 10
physicians) was followed at three time points, before us-
ing montelukast and 4 and 8 weeks after using monte-
lukast. We compared FEV1, number of salbutamol inha-
lations and general condition of patients before, and one
and two months after use of montelukast.
FEV1 before use of montelukast was 71%. Four weeks
after using montelukast average FEV1 increased to 79%
(p<0.001) and to 80% after 8 weeks of using monte-
lukast (statistically significant difference comparing to
starting value, p<0.001), (Figure 4).
An average number of salbutamol inhalations per
day before starting montelukast were 1.7. The average
number of inhalations per day decreased to 1.3 after 4
weeks of using montelukast, decreasing further to 0.9
inhalations per day after 8 weeks of using montelukast.
Differences between all groups were statistically signifi-
cant with p<0.05, (Figure 5).
Then we compared general condition of patients be-
fore, and 4 and 8 weeks after use of montelukast. Before
montelukast general condition of patients was at aver-
age graded as 0.7. One month after using montelukast
average grade was 1.5 and this was a statistically signif-
icant difference, p<0.001. Two months after using mon-
telukast a general condition was graded as 1.7 which is
also significant improvement comparing with starting
value (Figure 6).
Discussion
The present study was designed to determine the ef-
ficacy and safety of montelukast in asthma treatment.
We also tried to find out what are the most commonly
prescribed medications for asthma treatment.
According to the GINA classification asthma is di-
vided in two major groups: intermittent and persistent
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TABLE 1
BENEFITS OF MONTELUKAST IN PHYSICIANS' POINT OF VIEW
N %
Decreased need for asthma therapy (ICS, B2A) 135 22
Improvement in FEV1, no symptoms 85 14
Disappaerance of night symptoms, no functional
changes
65 11
Quick acting, patient without symptoms 49 8
No need for salbutamol 48 8
No use, no changes, non significant 39 6
Improvement in physical activity 34 6
Possibility to decrease corticosteroid dose 28 5
Normal auscultatory findings, patient stable 27 4
Less intense, shorter attacks 21 3
Good effect on lower and upper airways 12 2
Less exacerbations 10 2
FEV1 – forced expiratory volume in first second
TABLE 2
BENEFITS OF MONTELUKAST IN PATIENTS POINT OF VIEW
N %
I feel good, no cough 130 21
Dissapaerance of night symptoms 80 13
Less intense and shorter asthma attacks 71 12
Decreased need for Ventolin 65 11
No change 63 10
No dyspnea in physical activity 59 10
I feel healthy, better quality of life 51 8
No problems with nose or breathing 50 8
I breath easier, less weigth in lungs 24 4
Vomitting, nausea, vertigo, headache 9
I feel worse 5 1
Decreased dose of corticosteroids or claritine 4 1























Fig. 6. Improvement in patients’ general condition after 4 and 8


























Fig. 5. Number of salbutamol inhalations before and 4 and 8















Fig. 4. FEV1 (forced expiratory volume in first second) before
and 4 and 8 weeks after using montelukast.
regarding presence of day and night symptoms and also
regarding lung function. Persistent asthma is further
divided to mild, moderate and severe.
The study was done from October 2000 to March
2001, and data were collected via questionnaire given to
patients through their physicians. Patients were di-
vided in two major groups: the first followed at two time
points consisted of 612 patients and the second con-
sisted of 91 patients followed in three time points.
Many drugs are used in asthma management today,
and most commonly prescribed drugs in Croatia for
asthma treatment are inhaled corticosteroids, long last-
ing 2-agonists, long lasting theophyllins and oral cor-
ticosteroids. Other groups like antihistamines, amino-
phyllinum and chromones are much less prescribed.
Therefore, as leukotriene-antagonists are new group
of drugs in asthma treatment we tried to determine the
efficacy and safety of montelukast, one of the leuko-
triene-antagonists, in treatment of asthma.
We find out statistically significant improvement in
patients' general condition after adding montelukast to
asthma therapy and we also showed that need for sal-
butamol inhalations decreased after use of montelu-
kast. Further we showed statistically significant im-
provement in FEV1 after adding montelukast to a pre-
vious asthma therapy.
Further we showed statistically significant improve-
ment in patients' general condition and in FEV1 and de-
creased number of salbutamol inhalations per day after
adding montelukast to asthma therapy in all levels of
asthma severity according to the GINA criteria (inter-
mittent, mild persistent and moderate persistent). The
benefit of montelukast on asthma control was greater in
more severe levels of asthma. The probable explanation
for that is that in more severe asthma, inflammation is
greater, regarding the fact that leukotrienes are inflam-
matory modulators. Montelukast is anti-inflammatory
drug with synergistic and additive effect with steroids.
We also showed that 75% of patients have improved
their condition and lung function after use of montelu-
kast in combination with other drugs previously used
for asthma treatment.
We tried to estimate the benefit of montelukast ac-
cording to physicians. Most frequent benefit mentioned
was a decreased need for other asthma drugs, improve-
ment in FEV1 and disappearance of night symptoms.
Only in 6% of patients there was no improvement after
using montelukast according to physicians.
The benefits of montelukast according to patients
were most frequently mentioned stoppage of cough, dis-
appearance of night symptoms and decreased number of
asthma attacks. Only 1% of patients, had side effects
like vomiting, nausea, vertigo and headaches. That is in
concordance with Rakusic et al. who noticed similar re-
sults in different asthma perception between physicians
and patients in a previous study. Physicians focus on
improvements in objective parameters (FEV1) produced
by efficient anti-asthmatic drugs, whereas patients fo-
cus on their inability to take part in daily activities and
the emotional burden of their disease.
In the second group of patients, which was followed
at three time points, before and then 4 and 8 weekss af-
ter adding montelukast to other asthma therapy we
showed a clinically significant improvement in general
condition and in FEV1 4 weeks after starting to use
montelukast. The difference between week 4 and week 8
was still present, though it was not clinically signifi-
cant. Further, number of salbutamol inhalations de-
creased 4 and 8 weeks after starting to use montelukast.
The differences were statistically significant. And in
this group we also noticed that in majority of patients
ther was a significant improvement between 4 and 8
weeks after starting to use montelukast.
Montelukast is leukotriene antagonist, a member of
group of drugs for asthma treatment called controllers.
Montelukast is used to control inflammation in the air-
way and therefore used to control asthma montelukast
has quick action so we did not expect additional benefit
after prolonged use of montelukast, (8 weeks after using
montelukast). Prolonged use of long lasting 2-agonists
causes tachyphylaxis so we wanted to see is this phe-
nomenon also present after prolonged montelukast us-
age. Our results have shown that benefit of montelukast
is even greater after prolonged use of montelukast. We
concluded that there was no tachyphylaxis after pro-
longed use due to even greater improvement in FEV1 af-
ter prolonged use of montelukast. The additional benefit
of montelukast in higher levels of asthma according to
the GINA criteria is explainable that a longer period of
time is required to achieve satisfactory asthma control.
Montelukast is a drug with few side effects, which is
used once a day so compliance was very good. Good com-
pliance also contributed and is necessary for further im-
provement in FEV1 and a general condition after pro-
longed use of montelukast.
We conclude that montelukast is an efficient drug
with little side effects and with a good compliance.
Montelukast managed to achieve a good asthma control,
therefore it has a significant place in asthma therapy.
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MONTELUKAST U LIJE^ENJU ASTME U HRVATSKOJ
S A @ E T A K
Cilj ove studije bio je odrediti u~inkovitost i sigurnost montelukasta dodanog ostalim lijekovima za lije~enje astme
u bolesnika sa blagom i srednje te{kom trajnom astmom. Podaci su sakupljeni preko upitnika koji su dani lije~nicima
i njihovim pacijentima. Bolesnici su bili podijeljeni u dvije grupe; prva, u kojoj su bolesnici pra}eni kroz 4 tjedna (612
bolesnika) i druga, u kojoj su bolesnici pra}eni kroz 8 tjedana (91 bolesnik). U pra}enih bolesnika dokazali smo sta-
tisti~ki zna~ajno pobolj{anje u FEV1 (forsirani ekspiratorni volumen u 1. sekundi), pobolj{anje op}eg stanja bolesnika
te smanjeno kori{tenje salbutamola. U drugoj skupini bolesnika, tako|er smo dokazali pobolj{anje u FEV1 i op}em
stanju, te smanjenje kori{tenja salbutamola u prva 4 tjedna pra}enja, te daljnji napredak u slijede}a 4 tjedna. Na
temelju rezultata ove studije zaklju~ujemo da je montelukast u~inkovit lijek sa vrlo malo nuspojava. Montelukast je
uspio posti}i dobru kontrolu astme, stoga ima zna~ajno mjesto u lije~enju bolesnika s astmom.
